



Implanet announces its 2018 financial calendar

Bordeaux, Boston, January 4th, 2018: IMPLANET (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, today announced today its schedule for the publication of financial information for 2018.

Dates*
January 23, 2018
March 14, 2018
April 23, 2018
May 18, 2018
July 11, 2018
September 19, 2018
October 9, 2018

(*): Press releases are published before market opens. Subject to modification.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com. Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Euronext[™] Growth market in Paris. The Company would like to remind that the table for monitoring the BEOCABSA, OCA, BSA and the number of shares outstanding, is available on its website: <u>http://www.implanet-invest.com/suivi-des-actions-80</u>

IMPLANET Ludovic Lastennet CEO Tel. : +33 (0)5 57 99 55 55 investors@implanet.com NewCap Investor Relations Julie Coulot Tel. : +33 (0)1 44 71 20 40 implanet@newcap.eu NewCap Media Relations Nicolas Merigeau Tel. : +33 (0)1 44 71 94 98 implanet@newcap.eu AlphaBronze

US-Investor Relations Pascal Nigen Tel.: +1 917 385 21 60 implanet@alphabronze.net

